ENTITY

Symbio Pharmaceuticals (4582 JP)

43
Analysis
Health Care • Japan
Symbio Pharmaceuticals Limited develops and commercializes prescription drugs n oncology, hematology and auto-immune disease for Japan and other Asia Pacific markets.
more
•11 Aug 2026 11:00•Issuer-paid

Symbio Pharmaceuticals (4582 JP): 1H FY12/26 flash update

Sales declined 27.3% YoY to JPY470mn, with operating loss increasing to JPY3.6bn from JPY2.2bn YoY. SG&A expenses rose 50.1% YoY to JPY4.0bn,...

Logo
97 Views
Share
•08 May 2026 14:00•Issuer-paid

Symbio Pharmaceuticals (4582 JP): Q1 FY12/26 flash update

Sales declined 11.6% YoY to JPY233mn, with gross profit down 14.6% YoY to JPY173mn, and SG&A expenses up 83.3% YoY to JPY2.5bn. Operating loss...

Logo
214 Views
Share
•06 Feb 2026 12:00•Issuer-paid

Symbio Pharmaceuticals (4582 JP): Full-year FY12/25 flash update

SymBio's FY12/25 sales dropped 46.7% YoY to JPY1.3bn, with an operating loss of JPY4.4bn and recurring loss of JPY4.6bn. The FY12/26 forecast...

Logo
136 Views
Share
•31 Oct 2025 09:00•Issuer-paid

Symbio Pharmaceuticals (4582 JP): Q3 FY12/25 flash update

Sales dropped 48.9% YoY to JPY971mn, with a gross profit margin of 71.6%, down 4.5pp YoY. Operating loss was JPY3.3bn, compared to a loss of...

Logo
466 Views
Share
•01 Aug 2025 15:00•Issuer-paid

Symbio Pharmaceuticals (4582 JP): 1H FY12/25 flash update

Sales dropped 49.7% YoY to JPY647mn, with a gross profit margin of 76.3%, down 1.3pp YoY. Operating loss reached JPY2.2bn, recurring loss...

Logo
194 Views
Share
x